Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
SiChuan Qian Li Beoka Medical Technology Co ROCE % Related Terms
SiChuan Qian Li Beoka Medical Technology Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SiChuan Qian Li Beoka Medical Technology Co ROCE % Chart
SiChuan Qian Li Beoka Medical Technology Co Annual Data
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) has a ROCE % of 0.61% as of Mar. 2026.
Is SiChuan Qian Li Beoka Medical Technology Co's ROCE % too high?
SiChuan Qian Li Beoka Medical Technology Co's current ROCE % is 0.61%. The Medical Devices & Instruments industry median ROCE % is 2.93. SiChuan Qian Li Beoka Medical Technology Co's value of 0.61% is 79.2% below this industry median. Overall, SiChuan Qian Li Beoka Medical Technology Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SiChuan Qian Li Beoka Medical Technology Co's ROCE % compare to ABT and SYK?
SiChuan Qian Li Beoka Medical Technology Co's ROCE % of 0.61% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.93. SiChuan Qian Li Beoka Medical Technology Co's value of 0.61% is 79.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.93, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SiChuan Qian Li Beoka Medical Technology Co's current ROCE % of 0.61% is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SiChuan Qian Li Beoka Medical Technology Co's current ROCE % is 0.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SiChuan Qian Li Beoka Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.98, compared to a current price of ¥27.12 — trading 50.8% above its estimated fair value. The current ROCE % is 0.61% and 79.2% below the Medical Devices & Instruments industry median of 2.93. SiChuan Qian Li Beoka Medical Technology Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199), the current ROCE % is 0.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) Overvalued in 2026?
Based on GuruFocus' analysis, SiChuan Qian Li Beoka Medical Technology Co stock appears to be overvalued.
The current stock price of ¥27.12 is trading 50.8% above its estimated GF Value™ of ¥17.98.
GuruFocus considers SiChuan Qian Li Beoka Medical Technology Co to be Significantly Overvalued.
Key valuation signals for BJSE:920199:
ROCE %: 0.61%
GF Value™: ¥17.98 vs. price of ¥27.12 (50.8% above fair value)
Industry Position: 79.2% below the Medical Devices & Instruments median
No single metric tells the full story. See the BJSE:920199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SiChuan Qian Li Beoka Medical Technology Co Ltd is an intelligent rehabilitation equipment manufacturer integrating research, development, production, sales, and service. Its product series comprises the Electrotherapy series, Heat therapy series, Force therapy series, Spa series, and Oxygen therapy series.
57GF Score
Get the complete analysis for BJSE:920199
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920199 has been successfully added to your 
